Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer. Print this page
, H R: R6 y: s
( c: }. R8 d+ U+ C, \( E# Q9 f8 |2 S
! S# }) E6 ^8 ^) E H) F& WSub-category:
. G6 V" u8 _! I) G* N4 G4 t+ b: LMolecular Targets 8 \( z8 Z6 E, k4 @( E9 h: y
e* {0 a* L3 [4 G4 ]
5 D3 S& e! `6 D, {* f! G) c& [
Category:* e4 V/ L* {1 {3 ?8 K) \* m
Tumor Biology * J( V- k( O( I1 X( R* ^- J8 @
# P! y' m1 E5 I7 t* c: w: x
, u1 T+ m; P7 V& f0 U
Meeting:
5 o) f; W, Y2 _2011 ASCO Annual Meeting
6 f: ~1 S* |( a- X4 v! r! k. x
0 O. v8 b( p9 \* C
# ~" K; E( }5 }! V9 l, X1 ]/ xSession Type and Session Title:2 [8 q6 ^, y9 M) P8 m
Poster Discussion Session, Tumor Biology
6 l) x$ Y0 F% Z& o& S, o1 ?. H) {, w6 F) ~$ }
4 x k$ p8 L- j. E6 k. O/ s7 FAbstract No:
2 c8 D" r' M- i+ I0 k, r8 {10517
2 H9 j* z: b. y4 k" f9 |- M/ Q4 L& U& M* M5 F
# R& i6 u# j( {- j4 V2 }/ h
Citation:2 \3 V( \) a- j+ V4 z
J Clin Oncol 29: 2011 (suppl; abstr 10517)
! C+ c1 k( s9 S, q0 p2 u. U9 T. g8 O& D1 Y7 Q
$ L; r" X# _: rAuthor(s):8 { w3 P9 M& d7 e/ f* K
J. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China
" B: M$ q y0 G9 u
: ^( a- c2 `" J% J( L) C/ r
/ Q* H/ }' J+ o: p( ]
; m+ A$ f9 \% f1 r, A" OAbstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.
. k Y" v u" T3 `* _+ W) X, K) f5 V% a
Abstract Disclosures- I1 B y. A: j3 z! o, ~( I; [6 \
/ i: R, F# \# o9 a3 U- K
Abstract:
6 O! p, _+ ^" x% l9 V9 q0 N+ O4 e8 Y
$ d& Y1 Z% c) S1 m0 n! O J
Background: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.
! U$ U6 k0 `- q, I; v
* j+ C4 c+ w* B# B; O) H2 j
. C% u( h$ S' e8 F7 x |